Last reviewed · How we verify
NCT05453851
A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors
Phase 1, PHASE2 trial testing Pancreatectomy in Benign Pancreatic Neoplasm in 12 participants. Not yet recruiting.
1 July 2029
Quick facts
| Lead sponsor | OHSU Knight Cancer Institute |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 July 2026 |
| Primary completion | 1 July 2029 |
| Estimated completion | 1 July 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pancreatectomy
- Quality-of-Life Assessment
- Treatment Planning
Conditions studied
- Benign Pancreatic Neoplasm — all drugs for Benign Pancreatic Neoplasm →
- Chronic Pancreatitis — all drugs for Chronic Pancreatitis →
- Recurrent Acute Pancreatitis — all drugs for Recurrent Acute Pancreatitis →
Sponsor
OHSU Knight Cancer Institute
Who can join
18 and older, any sex, with Benign Pancreatic Neoplasm or Chronic Pancreatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I/II trial assesses the safety and effectiveness of total pancreatectomy with islet cell autotransplantation for the treatment of patients with long-term pancreatic inflammation (chronic pancreatitis) and non-cancerous (benign) pancreatic tumors. Total removal of the pancreas (pancreatectomy) can be used to treat chronic pancreatitis, but it may result in diabetes. An islet cell autotransplantation involves removing cells from a patient's pancreas (the islet cells) and infusing them into the liver. Islet cells are responsible for producing hormones like insulin, reducing the occurrence of diabetes in patients undergoing total pancreatectomy. Total pancreatectomy with autologous islet cell transplant is an accepted and Food and Drug Administration-approved treatment for patients with chronic pancreatitis. However, patients with chronic pancreatitis and pancreatic tumors have historically not been candidates for this procedure due to concerns of spreading potentially cancerous cells to other parts of the body. This clinical trial evaluates the safety and effectiveness of this treatment in patients with chronic pancreatitis and benign pancreatic tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05453851
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pancreatectomy
Trials testing the same drug.
- NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P · NA · recruiting
- NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
- NCT05841706 — Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreat · EARLY_PHASE1 · terminated
- NCT05325736 — Improvement in Glycemic Response After Bariatric Surgery · recruiting
- NCT04594772 — Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma · Phase 2 · active not recruiting
Other OHSU Knight Cancer Institute trials
Trials by the same sponsor.
- NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
- NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
- NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting
- NCT07278440 — An Exercise Intervention for Improving Mental and Physical Health in Patients With Primary Brain Tumors and Their Caregi · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05453851 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
- Last refreshed: 25 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05453851.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing